Skip to main content

BioLamina

MaterialsSundbyberg, SwedenFounded 2009· One of 955 Materials companies tracked by AMPulse

Develops and supplies recombinant laminin-based cell culture matrices and bioinks for 3D bioprinting and stem cell research, enabling biologically relevant 3D cell culture environments.

CEO / Founder
Klaus Langhoff-Roos
Team Size
51-200
Stage
Active
Total Funding
$20.4M
Latest Round
Venture Round
Key Investors
Lauxera Capital Partners; Bure Equity AB; Northislet AB

Technology & Products

Key Products

Biolaminin® isoforms; Biosilk 3D culture matrix; Bioink products (via partnerships)

Technological Advantage

Scientifically proven to increase cell proliferation rates with stable phenotype; only provider of full-length, human recombinant laminins; materials are defined, xeno-free, and regulatory-compliant.

Differentiation

Value Proposition

Provides defined, animal-origin-free laminin matrices that improve cell proliferation, differentiation, and phenotype stability in 2D and 3D cultures, accelerating stem cell research and therapy development.

How They Differentiate

Offers full-length human recombinant laminins (vs. animal-derived or fragment-based alternatives) with proven efficacy in 3D bioprinting applications; partnerships with leading bioprinter manufacturers like CELLINK provide integrated bioink solutions.

Market & Competition

Target Customers

Research institutions, biopharmaceutical companies, cell therapy developers, and bioprinting companies

Industry Verticals

Biotechnology; Pharmaceuticals; Regenerative Medicine; Research

Competitors

Corning Matrigel; Thermo Fisher Scientific; STEMCELL Technologies; R&D Systems

Growth & Milestones

Growth Metrics

About 90 employees as of August 2024, scaling to 119 by April 2026; global presence with offices in Sweden (Sundbyberg) and USA (Cambridge, MA).

Major Milestones

Founded in 2008; Partnership with CELLINK for bioink development (2020s); $20.36M Venture Round (Sept 2023); Klaus Langhoff-Roos appointed CEO (Aug 2024); €20M EIB venture debt financing (April 2026)

Notable Customers

Novo Nordisk, Pluristyx, Cell X Technologies

https://biolamina.com

Why this company matters

BioLamina occupies a niche position in the cell culture and bioprinting materials market by offering full-length human recombinant laminins, replacing animal-derived or fragment-based alternatives such as Corning Matrigel. Its proprietary technology mimics natural cell-matrix interactions, enabling biologically relevant 2D and 3D cell culture environments that support stem cell research and therapy development.

The company's core product line includes Biolaminin isoforms, a Biosilk 3D culture matrix, and bioink products developed through partnerships. These materials are defined, xeno-free, and regulatory-compliant, addressing reproducibility challenges in stem cell and primary cell culture. BioLamina's laminin-521 has been used in protocols for obtaining retinal pigment epithelium cells, and the company holds a portfolio of patents related to recombinant laminin compositions and applications.

Target customers include research institutions, biopharmaceutical companies, cell therapy developers, and bioprinting firms. Named customers include Novo Nordisk, Pluristyx, and Cell X Technologies. Key partnerships with CELLINK (BICO) provide integrated bioink solutions for bioprinter users, while collaborations with FyoniBio and Alder Therapeutics extend its reach into drug development and regenerative medicine.

BioLamina has raised approximately $20.36 million from investors including Lauxera Capital Partners and Bure Equity AB. With offices in Sweden and the USA and a global presence, the company is positioned to serve the growing demand for standardized, animal-free cell culture substrates in bioprinting and cell therapy manufacturing. Its main competitive risk lies in the dominance of established animal-derived matrices and the potential for competing recombinant or synthetic alternatives to gain adoption.